Unibest

Pharmaceutical intermediates

Capmatinib Hydrochloride Intermediates

1 pharmaceutical intermediate for Capmatinib Hydrochloride. Indication: Non-small cell lung cancer.

提交项目All intermediates

About Capmatinib Hydrochloride

Originator
Incyte Corp; Novartis Pharmaceutical Corp
Indication
Non-small cell lung cancer
Approved Date
05/06/2020
DS/DP
11/19/2027

Available intermediates

1 intermediate currently listed for Capmatinib Hydrochloride. Request specifications, documentation or a quotation for any item below.

Capmatinib Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
1-[2-Chloro-1-hydroxy-3-(6-quinolinyl)propyl]-2,5-pyrrolidinedione1197377-31-3//

Other programs under C

Cabozantinib S-malateCalcipotriolCalcitriolCamlipixantCanagliflozinCangrelor TetrasodiumCapivasertib Carfilzomib

Building toward Capmatinib Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →